Key Points
- EVP Kyle Jenne sold 1,823 shares on Jan. 16 at an average price of $75.96 for a total of $138,475.08, reducing his position by 10.01% to 16,389 shares (valued at ~$1.245M), according to an SEC filing.
- Broader insider selling occurred the same day, with multiple executives (including the CEO) selling roughly 117,000 shares totaling about $8.8M, a concentration of sales that may weigh on investor sentiment.
- Analyst and company outlook: MarketBeat shows a consensus "Moderate Buy" with a $87.05 target; Ionis has a $12.56B market cap, a negative P/E, and recently beat revenue estimates while narrowing its EPS loss.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Kyle Jenne sold 1,823 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average price of $75.96, for a total value of $138,475.08. Following the completion of the transaction, the executive vice president owned 16,389 shares of the company's stock, valued at $1,244,908.44. This trade represents a 10.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Ionis Pharmaceuticals Trading Up 1.6%
NASDAQ IONS opened at $77.53 on Wednesday. The business's fifty day moving average is $78.90 and its 200-day moving average is $64.33. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78. The stock has a market capitalization of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $86.15.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. The business had revenue of $156.72 million during the quarter, compared to the consensus estimate of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The firm's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.95) earnings per share. Equities research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in IONS. Capital World Investors grew its holdings in Ionis Pharmaceuticals by 1.5% during the 3rd quarter. Capital World Investors now owns 12,722,728 shares of the company's stock valued at $832,321,000 after buying an additional 182,540 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Ionis Pharmaceuticals by 253.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company's stock valued at $150,138,000 after acquiring an additional 2,724,400 shares during the period. Tweedy Browne Co LLC grew its stake in Ionis Pharmaceuticals by 0.3% during the third quarter. Tweedy Browne Co LLC now owns 2,901,216 shares of the company's stock valued at $189,798,000 after acquiring an additional 9,268 shares in the last quarter. Geode Capital Management LLC grew its stake in Ionis Pharmaceuticals by 1.7% during the second quarter. Geode Capital Management LLC now owns 2,891,095 shares of the company's stock valued at $114,245,000 after acquiring an additional 48,141 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in Ionis Pharmaceuticals by 190.3% during the 3rd quarter. American Century Companies Inc. now owns 1,372,225 shares of the company's stock worth $89,771,000 after acquiring an additional 899,476 shares during the period. Institutional investors own 93.86% of the company's stock.
Trending Headlines about Ionis Pharmaceuticals
Here are the key news stories impacting Ionis Pharmaceuticals this week:
- Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
- Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
- Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
Bennett filing
Birchler filing
Devers filing
Hougen filing
Jenne filing
Kordasiewicz filing
Monia (CEO) filing
O'neil filing
Schneider filing
Swayze filings
Analysts Set New Price Targets
IONS has been the subject of several research reports. Wall Street Zen lowered Ionis Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, November 1st. Leerink Partners increased their price target on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, December 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 8th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $89.00 price objective (up from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. Finally, Needham & Company LLC increased their target price on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $87.05.
Read Our Latest Stock Report on Ionis Pharmaceuticals
About Ionis Pharmaceuticals
(
Get Free Report)
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
